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Abstract  
BACKGROUND: Visfatin is an intracellular enzyme, known as nicotinamide phosphoribosyltransferase (Nampt) 
and pre-B-cell colony-enhancing factor (PBEF-1). It has insulin-mimetic effects and lowers plasma glucose levels.  
AIM: The aim of the work was to assess serum concentration of Visfatin in type 1 diabetic children and 
adolescents and study its relationships with duration of diabetes, body mass index (BMI), glycemic control, insulin 
dosage, lipid profile and microvascular complications.  
MATERIAL AND METHODS: Fifty children and adolescents with type 1 diabetes mellitus were recruited with 30 
ages and gender-matched healthy subjects. They were subjected to history taking; anthropometric measurements 
and chronic diabetic complications were recorded if present. Laboratory analysis included urinary microalbumin, 
serum triglycerides, HDL, LDL, cholesterol, fasting blood glucose, glycosylated Hb (HbA1c) and serum visfatin 
which was measured with enzyme-linked immunosorbent assay.  
RESULTS: Diabetic patients showed highly significant decrease in the level of visfatin compared to the control 
group (P = 0.0001).There was significant further decrease in visfatin level in diabetics with microalbuminuria (n = 
13) compared to normoalbuminuric patients (n = 37) (P = 0.015). There was highly significant inverse correlation 
between visfatin level with age (r = -0.379, p = 0.007), BMI (r = -0.418, p = 0.003), waist circumference (r = -
0.430, p = 0.002), hip circumference (r = -0.389, p = 0.005) and microalbuminuria (r = -0.323, p = 0.022).  
CONCLUSIONS: Type 1 diabetic children and adolescents had a significantly lower visfatin level compared to 
controls. A marked decrease in the level of visfatin was shown in patients with microalbuminuria with an inverse 
correlation with BMI suggesting an important role of visfatin in the pathogenesis of type 1 diabetics and type 1 
diabetic nephropathy. 
 
 
 
 
Introduction 
 
Children with prolonged hyperglycemia in 
Type 1 diabetes are exposed to long-term 
dysfunction, and failure of various organs especially 
the eyes, kidneys, and blood vessels [1]. Visfatin is a 
ubiquitous intracellular enzyme, known as 
nicotinamide phosphoribosyl transferase (NAMPT) 
and pre-B-cell colony-enhancing factor (PBEF-1). It is 
also identified as a novel adipocytokine [2]. It is 
preferentially produced in visceral adipose tissue and 
expressed in the isolated subcutaneous adipose cells 
as well. Both tissue expression and plasma levels of 
visfatin increase in parallel with obesity. Visfatin has 
insulin-mimetic effects and lowers plasma glucose 
levels [3, 4]. Also, high glucose levels markedly 
increased visfatin synthesis in cultured adipocytes [5]. 
Moreover, circulating visfatin concentrations were 
shown to increase in parallel with hyperglycemia [6]. It 
was first reported that patients with uncomplicated 
type 2 diabetes mellitus had elevated plasma visfatin 
levels [7]. Conversely, plasma visfatin levels were 
reported to be decreased in women with gestational 
diabetes mellitus (DM) [6]. Visfatin expression and 
plasma levels of visfatin were associated with 
obesity, insulin resistance and the level of 
albuminuria in type 2 diabetic patients [8]. Previous 
work is studying visfatin levels in populations with 
abnormal glucose metabolism which was not 
primarily associated with insulin resistance, like type 
1 DM, are very limited [4, 6, 9]. The aim of this work 
was to assess plasma concentration of visfatin in 
type 1 diabetic children and adolescents in 
comparison with healthy controls. Further, the 
possible relationships between visfatin and duration 
of diabetes, body mass index (BMI), glycemic 
control, insulin dosage, lipid profile and 
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microvascular complications were investigated.  
Materials and Methods 
 
Fifty children and adolescents previously 
diagnosed with type 1 diabetes mellitus were recruited 
from the Pediatric Diabetic Clinic, Children’s Hospital, 
Ain Shams University together with 30 age and sex-
matched healthy children and adolescents served as 
the control group. The age range for screened 
subjects was between 6 and 16 years old. They had 
disease duration of 5.63 ± 3.79 years with range (1- 
15 years). Exclusion criteria: chronic renal disease, 
chronic liver disease, heart failure, acute or chronic 
infections, malignancy. The study's protocol was 
approved by the ethical and research committee of 
the Council of Faculty of Medicine, Ain Shams 
University as well as by the ethical committee of the 
National Research Centre. Consents were taken 
after an explanation of the study and before the 
initiation of the research study.  
 
Methods 
Children were subjected to history taking to 
fulfill needed data: Insulin therapy, regarding dose in 
units/kg and type, history suggestive of acute 
metabolic complications, as hypoglycemic attacks 
(sweating, headache, blurring of vision, tremors, 
convulsions, and coma), diabetic ketoacidosis (DKA), 
history suggestive of chronic diabetic complications 
as ocular manifestations (persistent blurring of vision 
flashes of light), Peripheral neuropathy manifestations 
(tingling, numbness and paresthesia), clinical 
examination with special emphasis on 
anthropometric measures as wt, ht, and Standard 
deviation score (SDS) of height for age and weight for 
height [10].  
Body Mass Index (BMI) was calculated by 
applying the formula: BMI = weight in kg/ (height in 
m²). Once BMI is calculated for a child or 
adolescent, i t  is plotted by age on the Egyptian sex-
specific growth chart. According to the Center for 
Disease Control and Prevention [11]: Severe obesity: 
BMI ≥97
 th
 percentile for their age; Obese: BMI is ≥95
 
th
 percentile for their age; Overweight: BMI ≥85
 th
 
percentile and below the 95
th
 percentile; Normal 
weight: BMI ≥5
 th 
percentile and below the 85
th
 
percentile. 
 
Laboratory investigations 
Evaluation of Urinary microalbumin was done 
by using the SERA-PAK immune-microalbumin kit 
(Bayer Corporation Benedict Ave, Tarry Town, NY, 
USA). Persistent microalbumin excretion rate of 30-
300 mcg/mg creatinine by an immune turbid metric 
method in 3 repeated samples. It is used to assess 
the presence of nephropathy [12]. 
 
Serum Sample Collection 
About 5 cc venous blood were withdrawn from 
each child after overnight fasting (about 8-12 hrs.). 
After separation of serum, the following laboratory 
tests were done: Determination of complete lipid 
profile (serum triglycerides, HDL, LDL cholesterol).  
Fasting blood glucose was assessed using 
the enzymatic method on Hitachi instrument [13]. 
Glycosylated Hb (HbA1c) was measured using HPLC 
(high purified liquid chromatography) [14]. Then serum 
was divided into aliquots and kept at -20°C till used for 
the determination of serum visfatin. Serum visfatin 
was assessed by Enzyme Linked Immunosorbent 
Assay (ELISA). This kit was supplied by Glory 
Science. 
 
Statistical Analysis 
The standard computer program Statistical 
Package for Social Science (IBM SPSS) version 21 
was used for data entry and analysis. The comparison 
between groups with qualitative data was done by 
using Chi-square test and Fisher exact test instead of 
Chi-square only when the expected count in any cell 
found less than 5%. The comparison between two 
independent groups with quantitative data and 
parametric distribution were done by using an 
independent t-test, while the comparison between 
more than two groups was done by using One-Way 
Analysis of Variance (ANOVA). Spearman correlation 
coefficients were used to assess the relation between 
two quantitative parameters in the same group and 
also partial correlation was used to assess the relation 
between two parameters in the same group after 
adjusting the effect of other parameters. The p-value 
was considered significant if P < 0.05. 
 
 
Results  
 
As regard visfatin, there was a highly 
significant decrease in the level of serum visfatin in 
the diabetic patients’ group than the control group. 
The mean serum level of visfatin in control is (28.71 ± 
8.27), calculating the lower cut point = Mean - 2 S.D = 
12, so our cases were considered to have a 
physiologically low visfatin level if < 12 (ng/ml).  
The study showed that 24 patients (48%) had 
visfatin level <12 (ng/ml), while 26 patients (52%) had 
visfatin level ≥ 12 (ng/ml). It also showed that the 
median of visfatin level in type 1 diabetic patients was 
12.05 (Table 1).  
The distribution of microalbuminuria in 13 
patients (26%), neuropathy in 8 patients (16%) and 
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retinopathy in 3 patients (6%) among the type 1 
diabetic patients group is shown in Table 2. There 
was a significant increase in age, DM duration, insulin 
dose, BMI, waist/ht, Ht SD, cholesterol level, HDL, 
LDL microalbuminuria and a decrease in visfatin level 
in diabetic patients with complications (Table 2).  
Table 1: Comparison between type 1 diabetic patients versus 
healthy subjects regarding growth and laboratory results 
 
Patients group 
N=50 
Healthy subjects group 
N=30 
Independent t-test 
Mean SD Mean SD t P- value 
Ht. sds -0.31 1.06 0.09 1.26 1.510 0.135 
Wt. sds 1.10 1.64 1.45 1.62 0.909 0.366 
Triglyceride (mg/dL) 77.76 24.79 62.63 22.97 -2.714 0.008 
Cholesterol(mg/dL) 175.40 30.85 150.73 20.46 -3.891 0.0001 
HDL (mg/dL) 51.40 14.56 47.33 16.84 -1.140 0.258 
LDL (mg/dL) 109.72 31.43 95.00 14.53 -2.411 0.018 
HbA1c (gm%) 8.82 1.38 4.59 0.23 -16.564 0.0001 
Visfatin (ng/ml) 
Patients group 
N=50 
Healthy subjects group 
N=30 
Independent t-test 
Mean ± SD Range Mean ± SD Range t P-value 
11.26 ±5.84 0.1 –25.10 28.71±8.27 15 – 47.6 11.040 0.0001 
Ht = height, Wt = weight, HDL = high density lipoproteins, LDL = low density lipoproteins, 
HbA1c = glycated haemoglobin. 
 
There was significant increase regarding age, 
duration, insulin dosage, height SDS, BMI, waist, hip 
and waist to hip in microalbuminuric patients than that 
in normoalbuminuric (Table 3).  
Table 2: Effect of presence of complications of Type I DM on 
different studied parameters 
 1=No Complications 
2= With 
Complications 
 
No 
 
Mean 
 
Std. Deviation 
 
Sig. 
(2-tailed) 
Age 1 36 11.00 3.16 0.000 
2 14 15.14 2.18 
T1DM 
Duration Years 
1 36 4.10 2.85 0.000 
2 14 9.57 3.03 
Insulin dose 1 36 0.94 0.23 0.020 
2 14 1.12 0.24 
BMI 1 36 19.12 3.53 0.001 
2 14 22.82 3.22 
Waist/Hip 1 36 0.83 0.05 0.394 
2 14 0.82 0.05 
Waist /HT 1 36 0.45 0.03 0.003 
2 14 0.48 0.05 
Ht SD 1 36 -0.10 1.05 0.021 
2 14 -0.86 0.93 
Wt SD 1 36 1.10 1.78 0.983 
2 14 1.11 1.26 
Triglycerides (mg/dL) 1 36 75.22 18.65 0.250 
2 14 84.29 36.29 
Cholestero l(mg/dL) 1 36 169.72 25.41 0.035 
2 14 190.00 39.11 
HDL (mg/dL) 1 36 55.14 13.56 0.003 
2 14 41.79 12.89 
LDL (mg/dL) 1 36 102.28 24.37 0.006 
2 14 128.86 39.70 
HbA1c (gm%) 1 36 8.68 1.20 0.251 
2 14 9.18 1.77 
Fast Bl  
Sugar (mg/dL) 
1 36 148.75 43.75 0.476 
2 14 138.79 44.98 
Microalbuminuria 1 36 16.45 6.79 0.000 
2 14 69.29 30.95 
Visfatin (ng/ml) 1 36 12.19 6.15 0.035 
2 14 8.86 4.24 
T1DM = Type 1 Diabetes Mellitus, BMI = Body Mass Index, Ht = height, Wt = weight, HDL 
= high density lipoproteins, LDL = low density lipoproteins, HbA1c = glycated haemoglobin. 
 
It also showed that there was a significant 
decrease in the level of visfatin in patients with 
microalbuminuria than in normoalbuminuric patients. It 
also shows that there was a highly significant increase 
in the incidence of occurrence of neuropathy and 
retinopathy in microalbuminuric than normoalbumi-
nuric patients (Table 4).  
There was a highly significant inverse relation 
between visfatin level with age, height, weight, BMI, 
waist, hip and microalbuminuria (Table5 and Figure 
1).  
Table 3: Comparison of demographic and anthropometric 
measurements in type I DM patients with normal- versus micro-
albuminuria 
 Normoalbuminria 
N = 37 
Microalbuminuria 
N = 13 
Independent 
t-test 
Chi square 
Mean SD Mean SD t/x2 P-value 
Age years 11.14 3.22 15.08 2.25 -4.060 0.0001 
Male 
Female 
18 
19 
48.6% 
51.4% 
4 
9 
30.8% 
69.2% 
1.248 0.264 
Disease Duration [Y] 
Duration (years) 
4.23 2.92 9.62 3.15 -5.601 0.0001 
Insulin dosage 
dosage (I.U/kg/day) 
0.95 0.23 1.13 0.25 -2.463 0.017 
Ht.sds -0.11 1.03 -0.88 0.97 2.353 0.023 
Wt. sds 1.12 1.76 1.05 1.29 0.134 0.894 
BMI 19.28 3.60 22.66 3.29 -2.976 0.005 
Waist circumference 
(cm) 
63.22 6.90 74.88 10.35 -4.578 0.0001 
Hip circumference 
(cm) 
76.22 12.42 91.73 13.38 -3.799 0.0001 
Waist \ hip 0.84 0.05 0.82 0.05 1.003 0.321 
Waist \ ht 0.45 0.03 0.49 0.05 -3.290 0.002 
 Ht = height, Wt = weight, BMI = Body Mass Index. 
 
The multiple linear regression analysis using 
stepwise method shows that BMI is the most 
important predictor that affects visfatin level in the 
patient's group (Table 6). 
Table 4: Comparison of laboratory data and presence or 
absence of complications in diabetic patients with normal- 
versus micro- albuminuria 
 Norm albuminuria 
N=37 
Microalbuminuria 
N=13 
Independent 
t-test 
Mean SD Mean SD t/x2 P-value 
Triglycerides (mg/dL) 75.11 18.40 85.31 37.56 -1.284 0.205 
Cholesterol (mg/dL) 170.38 25.37 189.69 40.69 -2.001 0.051 
HDL (mg/dL) 55.38 13.45 40.08 11.64 3.645 0.001 
LDL (mg/dL) 102.59 24.10 130.00 41.08 -2.902 0.006 
HbA1c (gm%) 8.66 1.19 9.27 1.81 -1.387 0.172 
Fasting blood 
glucose (mg/dL) 
147.49 43.81 141.62 45.50 0.412 0.682 
Visfatin (ng/ml) 12.20 6.07 8.59 4.29 2.444 0.015 
Complications Norm albuminuria  
N = 37 
Microalbuminuria  
N = 13 
Chi square test 
No. % No. % X2 P-value 
Neuropathy Negative 
Positive 
36 
1 
97. 
32.7 
6 
7 
46.2 
53.8 
 
18.722 
 
<0.0001 
Retinopathy Negative 
Positive 
37 
0 
100 
0.0 
10 
3 
76.9 
23.1 
9.083 0.003 
 HDL = high density lipoproteins, LDL = low density lipoproteins, HbA1c = glycated 
haemoglobin. 
 
 
Discussion 
 
Visfatin exerts insulin-mimetic effects that are 
dose dependent and quantitatively similar to those of 
insulin in stimulating muscle and adipocyte glucose 
transport and in inhibiting hepatocyte glucose 
production [7]. However, visfatin and insulin did not 
compete for binding to the insulin receptor, indicating 
that the two proteins were recognised by different 
regions of the receptor [3]. 
This study revealed that diabetic patients had 
a significantly lower visfatin level compared to the 
healthy controls although there was no significant 
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difference between the two studied groups as 
regarding demographic and anthropometric 
measures. This result comes by the previous studies 
done by Toruner et al. (2009), who studied circulating 
plasma visfatin levels in 48 adult patients with type 1 
diabetes mellitus (mean age 26 ± 86 years) and found 
visfatin levels to be decreased in diabetic patients [4]. 
Table 5: Correlation between visfatin level & the studied 
parameters of type 1 diabetic patients group 
  Visfatin   Visfatin 
 r P-value  r P-value 
Age -0.379** 0.007 Syst .bl.pr -0.035 0.811 
Disease Duration  -0.225 0.117 Diast.bl.pr -0.138 0.340 
Insulin Dosage 0.022 0.878 Triglycerides -0.011 0.939 
BMI -0.418** 0.003 Cholesterol -0.256 0.072 
Waist circumference -0.430** 0.002 HDL 0.070 0.628 
Hip circumference -0.389** 0.005 LDL -0.203 0.158 
Waist\hip ratio 0.17 0.213 HbA1c 0.120 0.408 
Waist\ht ratio -0.275 0.053 Fasting Bl Glucose 0.012 0.932 
Ht.sds 0.195 0.174 Microalbuminuria -0.323* 0.022 
Wt. Sds -0.238 0.096    
BMI = Body Mass Index, Ht = height, Wt = weight. 
 
Similarly, Alexiadou et al. [15] study on type 1 
diabetic adult patients found that fasting visfatin levels 
tended to be lower in patients with type 1 diabetes in 
comparison to healthy subjects. 
Table 6: Stepwise multiple linear regression analysis for the 
predictors of visfatin 
Model 
 Unstandardized 
Coefficients 
Standardized 
Coefficients 
 
t 
 
Sig. 
visfatin. 
B Std. Error Beta 
Constant 21.902 4.269  5.130 0.000 
BMI -0.528 0.208 -0.344 -2.536 0.015 
 
While another study performed on type 1 
diabetic patients to study the effect of exercise on 
visfatin Haider et al. [6] reported increased plasma 
visfatin levels compared with controls in a relatively 
small group of adolescent patients with type 1 DM. 
Similarly, López-Bermejo et al. [9] reported that serum 
visfatin levels increase with β -cell dysfunction both in 
type 2 and long-standing type 1 diabetic patient. The 
reason of controversial data about visfatin 
concentrations in type 1 DM is not clear [4]. This 
discrepancy may, in part, be due to different study 
populations as our diabetic patients are younger and 
had a shorter duration of diabetes and higher HbA1c 
levels than the other study groups. Another reason 
could be the administration of a larger dose of 
exogenous insulin in our patient group as insulin can 
significantly suppress visfatin expression in the 
plasma and adipocytes [6]. 
In our study there was no relationship 
between visfatin and any of the measured values in 
the lipid profile, this data came corresponding with the 
results of the study made by Toruner et al. (2009) [4] 
on type 1 diabetic patients who found that visfatin 
concentrations did not correlate with the measured 
lipid parameters. Similarly, Dogru et al. [16] found no 
association between visfatin concentrations and lipid 
parameters in patients with type 2 diabetes.  
Figure 1: Correlation between visfatin level and BMI in the patients 
group (r = -0.418) (P = 0.003) 
 
On the other hand, Hassan et al. [17] study 
indicated a significant positive correlation between 
visfatin level and cholesterol and VLDL-C in males 
and females and only with triglycerides in females and 
positively with LDL-C in males and negatively with 
HDL-C in males and females. In contrast, a negative 
correlation was reported between visfatin and 
cholesterol, triglyceride and HDL-C [18]. They 
suggested that visfatin may participate in 
cardiovascular disease and may lead to 
hypercholesterolemia and hypertriglyceridemia [18]. 
Therefore, although visfatin level is known as an 
adipocyte- derived peptide, there seems to be no 
clear relationship between circulating visfatin 
concentrations and lipid levels [4]. 
Our study showed that there was no 
correlation between visfatin and age in control group 
while there was a significant inverse correlation 
between visfatin 1 level with age in type 1 diabetic 
patients group. This result comes in agreement with 
the study of Jin et al. [19] who stated that fasting 
serum visfatin levels show significantly negative 
association with age. In this current study, there was 
no significant relationship between visfatin level and 
HbA1c in the studied group after adjustment for age, 
sex, and BMI and disease duration. This comes in 
correspondence with El Mesallamy et al. [20] study 
which stated that unexpectedly, their study did not 
show a correlation between visfatin levels and HbA1c 
%. 
This study also showed a significant inverse 
relationship between visfatin levels and 
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microalbuminuria after adjustment for age, sex, BMI 
and disease duration. Visfatin is associated with 
declining glomerular filtration rate (GFR). Interestingly, 
glomerular mesangial cells have been shown to 
secrete visfatin under high glucose conditions [21], 
with visfatin being shown to increase angiotensinogen 
protein expression, which may increase renin-
angiotensin system activation, which would alter GFR 
[22]. Whereas Kang et al. [5] study on type 2 diabetic 
patients with and without microalbuminuria stated that 
plasma visfatin levels were significantly increased in 
type 2 diabetic patients irrespective of the degree of 
microalbuminuria. Yilmaz M, et al. studied subjects 
with early diabetic nephropathy having 
microalbuminuria but no renal dysfunction and found a 
significant association of visfatin with proteinuria [23]. 
Mahmood N et al. confirmed the association 
of visfatin with chronic kidney disease [24]. 
As regarding the relationship between visfatin 
and duration of illness in type 1 diabetic patients, we 
found no significant relationship between them. 
Similarly, Toruner et al. (2009) found that visfatin 
levels were not correlated with the duration of 
diabetes in univariate analysis, and similar visfatin 
levels were observed between the patients with a 
short and long duration of diabetes in our study group. 
However, regression analysis demonstrated that the 
duration of diabetes was a significant predictor of 
circulating visfatin concentrations [4]. In this respect, 
López-Bermejo et al. (2006) reported no association 
between visfatin and duration of diabetes in adult type 
1 diabetic patients with long-standing disease. 
Our study found that that there was a highly 
significant inverse relation between visfatin level and 
BMI. Multiple linear regression analysis using 
stepwise method shows that BMI is the most 
important predictor to affect visfatin level in the 
patient's group. These results come in 
correspondence with Samara et al. [25] who studied 
visfatin gene expression and relation to BMI, they 
found that Visfatin expression in peripheral blood 
mononuclear cells (PBMCs), was significantly 
associated with BMI in a negative way, and these 
associations remained significant after separating 
subjects into three groups (lean, overweight, obese) 
for men and women. There are conflicting clinical data 
about the association of visfatin levels with BMI [4]. 
Several studies demonstrated that plasma 
visfatin levels correlate with obesity, visceral fat mass, 
type 2 diabetes and the presence of the metabolic 
syndrome [7, 8, 26]. Compared with lean children, 
obese children had significantly higher serum leptin, 
visfatin [27]. Other studies, however, did not confirm 
an association of visfatin with visceral adipose tissue 
or parameters of insulin sensitivity in humans and 
rodents [28]. Dogru et al. [29] study revealed that 
visfatin levels did not correlate with BMI newly 
diagnosed type 2 diabetics while Toruner et al. (2009) 
did not observe any relationship between visfatin 
levels and BMI. Besides, Brendt et al. [30] study 
showed that there is a significant relationship between 
visfatin concentrations and BMI and the percentage 
body fat in non-diabetic subjects. In disagreement with 
our study López-Bermejo et al. [9]; Haider et al. [6] 
and Alexiadous et al. [15] stated no relationship 
between visfatin levels and BMI in type 1 diabetic 
subjects.  
This study has some limitations. One of these 
may be the lack of plasma visfatin concentrations 
before insulin treatment at the beginning of the 
diagnosis. The other is the lack of any data regarding 
follow-up of visfatin concentrations in type 1 diabetic 
patient. Further studies are required to enlighten these 
questions. 
In conclusion, this study revealed that diabetic 
patients had a significantly lower visfatin level 
compared to the healthy controls. The study also 
found that there is a statistically significant decrease 
in the level of visfatin in patients with microalbuminuria 
than in normoalbuminuric patients. In this study, there 
was no relationship between visfatin and any of the 
measured values in the lipid profile. A marked 
decrease in the level of visfatin was shown in patients 
with microalbuminuria with an inverse correlation with 
BMI suggesting an important role of visfatin in the 
pathogenesis of type 1 diabetics and type 1 diabetic 
nephropathy. 
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